December 30, 2013 — RaySearch Laboratories AB received two orders for its RayStation treatment planning system from the proton treatment centers Seattle ProCure Management LLC, Seattle, and Princeton ProCure Management LLC, Princeton, N.J. The two centers will use RayStation for treatment planning of proton radiation therapy.
“There are several reasons why we selected RayStation,” said Tony Wong, director of physics, Seattle ProCure Treatment Center, and Dennis Mah, director of physics, New Jersey ProCure Treatment Center. “The most important benefits are the breadth of technology, high speed of planning and dose computation and ease of analysis compared to other modalities. This is the best system currently available in terms of robust optimization, computational accuracy and ease of use.”
“ProCure is a well-known name in proton therapy, and given the strong partnerships between RaySearch, IBA and now Procure, we are confident that this is a big step forward for all of us and how proton planning can evolve,” said Marc Mlyn, president, RaySearch Americas.
The current version of RayStation that has U.S. Food and Drug Administration (FDA) clearance supports the proton treatment techniques Uniform Scanning and Double Scattering. Support for pencil beam scanning (PBS) / intensity-modulated proton therapy (IMPT) has been released in Europe with CE marking and 510(k) clearance in the United States for PBS is expected early 2014.
For more information: www.raysearchlabs.com
April 10, 2026 
